Home › Research › Biomarkers
Alzheimers disease blood biomarkers reveal proteomic modules of disease progression
Butler, R. R.; Brown, M. P.; Weber, A.; Cary, G. A.; Le Guen, Y.; Moran Losada, P.; Mendiola, J. H.; Henderson et al.. medRxiv (preprint), 2026-08-19
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimers disease (AD) unfolds over decades preceding cognitive symptoms, and measuring the full scope of its molecular complexity remains difficult. Blood-based biomarkers of amyloid, phosphorylated tau, astrocytic reactivity and neuroaxonal injury--including A{beta}42/40, p-tau181, p-tau217, GFAP and NfL--enable scalable assessment of AD-related pathology and associated processes but capture only a narrow slice of the systemic biology ultimately shaping disease progression. Here we link these increasingly routine clinical assays to the plasma proteome using multi-omic linear modeling to resolve functional heterogeneity in AD progression. In 484 older adults spanning normal cognition, mild cognitive impairment (MCI) and AD, we derived proteomic signatures for each key biomarker across more than 6,000 proteins, uncovering overlapping and distinct biological processes and cell types implicated in AD with robust signal across proteomic modalities. From these we built continuous progression-focused functional modules that were consistently preserved across 12 independent cohorts comprising 11,042 participants from the Global Neurodegeneration Proteomics Consortium and that associated with cognitive decline, diagnosis and AD-relevant biology. A synaptic vesicle module marked apparent neuronal resilience as much as 5 years before estimated symptom onset. We show routine and accessible plasma measures can be leveraged to recover reproducible, biologically distinct progression modules that improve characterization of heterogeneous AD and have practical value for risk stratification, trial enrichment, or treatment monitoring.
What this study adds
Evidence grade: Low
The record lists 11,042 participants. By linking routine Alzheimer's blood biomarkers to thousands of plasma proteins, the researchers built progression-related modules that held up across 12 independent cohorts and were tied to cognitive decline. One synaptic module marked apparent neuronal resilience up to five years before estimated symptom onset.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Butler, R. R., Brown, M. P., Weber, A., Cary, G. A., Le Guen, Y., Moran Losada, P., et al. (2026). Alzheimers disease blood biomarkers reveal proteomic modules of disease progression. medRxiv (preprint). https://doi.org/10.64898/2026.08.14.26360394
Vancouver
Butler RR, Brown MP, Weber A, Cary GA, Le Guen Y, Moran Losada P, et al. Alzheimers disease blood biomarkers reveal proteomic modules of disease progression. medRxiv (preprint). 2026. doi:10.64898/2026.08.14.26360394.
BibTeX
@article{butler2026-ab713afc,
author = {Butler, R. R. and Brown, M. P. and Weber, A. and Cary, G. A. and Le Guen, Y. and Moran Losada, P. and Mendiola, J. H. and Henderson and others},
title = {{Alzheimers disease blood biomarkers reveal proteomic modules of disease progression}},
journal = {medRxiv (preprint)},
year = {2026},
doi = {10.64898/2026.08.14.26360394},
url = {https://doi.org/10.64898/2026.08.14.26360394}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- From these we built continuous progression-focused functional modules that were consistently preserved across 12 independent cohorts comprising 11,042 participants from the Global Neurodegeneration Proteomics Consortium and that associated with cognitive decline, diagnosis and AD-relevant biology.
Why it matters
By linking routine Alzheimer's blood biomarkers to thousands of plasma proteins, the researchers built progression-related modules that held up across 12 independent cohorts and were tied to cognitive decline. One synaptic module marked apparent neuronal resilience up to five years before estimated symptom onset.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants11,042
- Evidence strengthLow
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 28 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 26 of the 94 points we could judge it on, which is 28 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv (preprint)) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 4 / 4 | 11,042 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 0 / 4 | Last-listed author Edward N. Wilson: h-index 2 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Stanford University: institution h-index 2,684 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 26 / 94 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 26 of the 94 points we could judge it on is 28 out of 100. |
| Total | 28 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.
Related studies in Biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.